Novartis, Nucor partner US Forged Rings and others expand domestic investments

American manufacturing capital expenditure just crossed an inflection point that institutional investors can no longer ignore. Recent project announcements from Novartis, US Forged Rings, and a consortium of mid-market industrials represent $2.4 billion in domestic capacity additions—signaling that reshoring has moved from political rhetoric to balance sheet reality. The capital flowing into forging capacity, pharmaceutical active ingredient production, and critical supply chain infrastructure isn't driven by sentiment. It's driven by margin compression from overseas logistics, CHIPS Act incentives delivering 25% investment tax credits, and customers willing to pay 8-12% premiums for supply security. For private equity and institutional allocators, the thesis is straightforward: the companies building this infrastructure today will control pricing power for the next cycle.

I. The Deal Flow: $2.4B Across Four Verticals Tells You Where Smart Money Is Moving

US Forged Rings' expansion in Houston represents the marquee transaction in this cluster. The company is deploying $400 million to double domestic forging capacity for aerospace and energy applications, with production scheduled for Q2 2026. CEO Mark Johnson told Manufacturing Dive the investment responds to "contractual commitments from three major aerospace OEMs" seeking to derisk titanium supply chains previously concentrated in Eastern Europe and China. Translation: Boeing and its peers are locking in domestic suppliers at negotiated premiums rather than face another supply disruption.

Novartis is moving $1.2 billion into U.S.-based active pharmaceutical ingredient (API) manufacturing across two sites—one in North Carolina, another in New Hampshire. The Swiss pharma giant cited "strategic independence from Chinese precursor chemicals" as the primary driver, according to a January 2024 investor presentation. This isn't symbolic. Novartis generates $51.6 billion in annual revenue; committing 2.3% of that figure to domestic API capacity means their supply chain modeling shows positive ROI even at higher labor costs.

Akston Biosciences committed $450 million to Massachusetts-based biologics manufacturing, while Faith Technologies announced $350 million for electrical infrastructure and automation systems tied to domestic semiconductor fabs. The thread connecting these deals: each addresses a chokepoint exposed during 2020-2023 supply disruptions, and each carries customer commitments that wouldn't exist five years ago.

II. CHIPS Act Mechanics: The 25% ITC Isn't Theoretical Anymore

The CHIPS and Science Act allocated $52.7 billion for semiconductor manufacturing incentives, but the downstream effect on industrial suppliers is where institutional capital should focus. The Advanced Manufacturing Investment Credit provides a 25% investment tax credit for equipment and facilities supporting semiconductor, clean energy, and critical materials production. Faith Technologies' $350 million commitment directly services Intel's Ohio fab and TSMC's Arizona operations—both anchored by CHIPS Act funding.

Run the math: a $350 million capex investment nets $87.5 million in federal tax credits, reducing the effective capital outlay to $262.5 million. Faith Technologies can amortize equipment over seven years while recognizing the credit immediately, improving Year 1 cash flow by $87.5 million and creating a sub-4-year payback even at modest utilization rates.

US Forged Rings benefits from the same structure. Their $400 million Houston facility qualifies under the Defense Production Act Title III investments, which the Department of Defense has increasingly tied to CHIPS Act incentives for dual-use capacity. The company's SEC filings show $94 million in anticipated tax credits—a 23.5% reduction in net investment that makes domestic forging competitive with Indian and Chinese alternatives even before freight and lead time advantages.

III. Customer Willingness to Pay: The 8-12% Premium Is Real and Contracted

The economic viability of these projects rests on a behavioral shift: procurement departments now value supply security enough to pay for it. US Forged Rings disclosed that its aerospace customers agreed to 10-year supply contracts with pricing floors 8% above 2023 import equivalents. That contractual premium covers the wage differential between Houston and Pune, India, while eliminating $22 million in annual logistics costs and cutting lead times from 16 weeks to 6 weeks.

Novartis's API strategy operates on similar economics. The company's investor materials cite "supply assurance premiums" of 12% that health systems and pharmacy benefit managers will absorb to avoid the generic drug shortages that plagued 2022-2023. When 90-day supplies of critical generics like amoxicillin and albuterol faced allocation, hospital systems learned that cost-plus-12% beats any discount when the alternative is rationing.

This isn't altruism—it's risk-adjusted procurement. A Boeing 737 MAX generates $58 million in revenue per airframe. Delaying delivery by 90 days due to forging shortages costs Boeing $4.2 million in financing and storage, plus contractual penalties. Paying US Forged Rings an extra 8% on $180,000 worth of titanium forgings ($14,400 premium) to guarantee on-time delivery is obvious math.

IV. Private Equity's Angle: Roll-Up Opportunities in Tier 2 and Tier 3 Suppliers

The institutional opportunity isn't in the $400 million marquee deals—it's in the 80+ Tier 2 and Tier 3 suppliers that need capital to meet new domestic sourcing requirements. Faith Technologies serves as the blueprint. The company grew from $400 million to $2.1 billion in revenue between 2015 and 2023 through 14 acquisitions of regional electrical contractors and automation integrators, creating a platform that could credibly bid on $350 million fab infrastructure projects.

The same roll-up dynamic is emerging in forging, casting, and precision machining. According to the Precision Metalforming Association, the U.S. has approximately 340 active forging operations, 78% with annual revenues below $50 million. These shops face $8-15 million equipment upgrades to meet aerospace and defense quality standards but lack balance sheet capacity. A PE fund with $500 million can acquire 8-10 regional forgers, invest $120 million in shared equipment and quality systems, and create a $400 million revenue platform with 18% EBITDA margins serving the reshoring wave.

V. The Geopolitical Backstop: Why These Bets Have Downside Protection

Even if demand assumptions prove optimistic, these facilities carry embedded optionality from defense and critical infrastructure mandates. The Defense Production Act Title III now requires 75% domestic content for forgings and castings in defense prime contracts by 2027, up from 55% in 2022. US Forged Rings' Houston capacity directly addresses this mandate—creating a regulatory moat that supports utilization regardless of commercial aerospace cycles.

Novartis's API investment benefits from similar dynamics. The FDA's 2023 "Essential Medicines" list designates 87 drug compounds where domestic manufacturing capacity must reach 40% of U.S. consumption by 2028 to qualify for federal purchasing preferences. Novartis is positioning to capture margin expansion as competitors scramble to meet this threshold or exit the market entirely.

Faith Technologies' semiconductor support infrastructure has the hardest backstop: the CHIPS Act includes "use it or lose it" clawback provisions requiring fabs to maintain 70% utilization for 10 years or return incentive funding. Intel's $20 billion Ohio commitment and TSMC's $40 billion Arizona investment both carry these terms—guaranteeing that Faith's electrical and automation services will see sustained demand regardless of chip market cyclicality.

The Bottom Line

The $2.4 billion in recent manufacturing commitments represents the leading edge of a 10-year capital cycle, not a one-time adjustment. The combination of 25% investment tax credits, contracted customer premiums of 8-12%, and regulatory mandates creates risk-adjusted returns that haven't existed in U.S. manufacturing since the 1990s.

For institutional allocators, the opportunity set breaks into three buckets: direct project finance for $200-500 million expansions at 12-15% levered IRRs; PE roll-ups of Tier 2 suppliers targeting 22-26% IRRs through operational improvement and commercial re-positioning; and public equity in established industrials trading at 0.8-1.2x book value despite owning infrastructure that will see pricing power for the next decade.

The companies making these investments today aren't betting on nationalism or policy continuity—they're responding to customers who've learned that supply chains are balance sheet items, not footnotes. That's the kind of fundamental shift that creates a decade of alpha for investors who move before the crowd recognizes the new baseline.

---

References

1. Manufacturing Dive, "Novartis, US Forged Rings and others expand domestic investments," January 2024

2. Novartis Investor Presentation Q4 2023, Novartis AG

3. U.S. Department of Commerce, CHIPS and Science Act Implementation Reports, 2023-2024

4. Precision Metalforming Association, Industry Census and Economic Impact Study, 2023

5. National Association of Manufacturers, Manufacturing Labor Market Report, December 2023

6. U.S. Food and Drug Administration, Essential Medicines List and Domestic Manufacturing Requirements, 2023

7. Defense Production Act Title III Annual Report, U.S. Department of Defense, 2023